Post-transplant lymphoproliferative disorder in children: Incidence, prognosis, and treatment options

被引：29

作者：

Faye A. ^{[1
,2
]}

Vilmer E. ^{[1
]}

机构：

[1] Service d'Hémato-Immunologie, Hôpital Robert Debré, Paris

[2] Service d'Hémato-Immunologie, Hôpital Robert Debré, Paris, 75019

来源：

Pediatric Drugs | 2005年 / 7卷 / 1期

关键词：

Hematopoietic Stem Cell Transplantation; Solid Organ Transplantation; Acute GVHD; Foscarnet; Solid Organ Transplantation Recipient;

D O I：

10.2165/00148581-200507010-00005

中图分类号：

学科分类号：

摘要：

Post-transplant lymphoproliferative disorder (PTLD) after solid organ or hematopoietic stem cell transplantation in children is a serious complication that has been responsible for high mortality rates over recent years. PTLDs are part of a clinically and histologically heterogeneous group of B-lymphocyte proliferations mostly induced by Epstein-Barr virus (EBV) in a context of immunosuppression. Major risk factors for PTLDs in solid organ transplantation are the EBV serostatus mismatch and the intensity, duration, and type of immunosuppression. T-cell depletion and the HLA-mismatched donor and recipient are the main risk factors following hematopoietic stem cell transplantation. For a long time, the only safe and effective therapeutic approach to PTLD was reduction of immunosuppression, with a risk of graft rejection. Based on a better knowledge of the pathophysiology and risk factors for PTLD, preventive and pre-emptive strategies have been recently proposed to control PTLD. New treatment modalities, such as anti-B-cell antibodies, cytokine inhibitor therapy, or anti-EBV cytotoxic T lymphocytes are promising and may improve the outcome of PTLD. These therapeutic approaches need to be further evaluated, especially in the context of pre-emptive strategies adapted to predictive markers of EBV-induced PTLD. © 2005 Adis Data Information BV. All rights reserved.

引用

页码：55 / 65

页数：10

共 84 条

[1]

Morrison V.A., Dunn D.L., Manivel J.C., Et al., Clinical characteristics of posttransplant lymphoproliferative disorders, Am J Med, 97, pp. 14-24, (1994)

[2]

Penn I., The changing pattern of post-transplant malignancies, Transplant Proc, 23, pp. 1101-1103, (1991)

[3]

Leyland V., Sutton L., Doreen R., Et al., Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center, J Oncol, 13, pp. 961-968, (1995)

[4]

Boubenider S., Hiesse C., Goupy C., Et al., Incidence and consequences of posttransplantation lymphoproliferative disorders, J Nephrol, 10, pp. 136-145, (1997)

[5]

Leblond V., Dhedin N., Mamzer Bruneel M.F., Et al., Identification of prognostic factors in 61 patients with post-transplantation lymphoproliferative disorders, J Clin Oncol, 19, pp. 772-778, (2001)

[6]

Rickinson A.B., Kieff E., Epstein-Barr virus, Fields Virology. 4th Ed., pp. 2575-2627, (2001)

[7]

Hanson M.N., Morrison V.A., Peterson B.A., Et al., Post-transplant T-cell lymphoproliferative disorders an aggressive, late complication of solid-organ transplantation, Blood, 88, pp. 3626-3633, (1996)

[8]

Kwong Y.L., Lam C.C., Chan T.M., Et al., Post-transplantation lymphoproliferative disease of natural killer cell lineage: A clinicopathological and molecular analysis, Br J Haematol, 110, pp. 197-202, (2000)

[9]

Nalesnik M.A., Jaffe R., Starzl T.E., Et al., The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression, Am J Pathol, 133, pp. 173-192, (1988)

[10]

Yandell D.W., Li C., Saini S., Et al., Brief report: Lymphoma of donor origin occurring in the porta hepatis of a transplanted liver, N Engl J Med, 329, (1993)

← 1 2 3 4 5 6 7 8 9 →